GlassScriptPhysician profile
Ryan James Shephard
NPI 1326722703
$6,588.83
in general payments reported to CMS, 2019-2025
33 companies · $2,755 in 2025
The $2,755 reported for 2025 was more than what 96% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $790 · 2024: $3,044 · 2025: $2,755.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,589.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,588.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,570.91 | 2023-2025 | Airsupra, Farxiga, Breztri |
| Amgen INC. | $782.39 | 2023-2025 | Otezla, Repatha, Repatha |
| Abbvie INC. | $624.26 | 2023-2025 | |
| Lilly USA, LLC | $581.75 | 2023-2025 | Mounjaro, Zepbound, Kisunla |
| Bayer Healthcare Pharmaceuticals INC. | $456.82 | 2023-2025 | |
| Novo Nordisk INC | $386.70 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $357.12 | 2023-2025 | |
| Astellas Pharma US INC | $264.12 | 2024-2025 | Veozah |
| Madrigal Pharmaceuticals | $221.15 | 2024-2025 | Rezdiffra, Resmetirom |
| Novartis Pharmaceuticals Corporation | $154.31 | 2024-2025 | |
| Otsuka America Pharmaceutical, INC. | $150.49 | 2024-2025 | Rexulti |
| Aimmune Therapeutics, INC. | $121.80 | 2024-2025 | Zenpep |
| Boehringer Ingelheim Pharmaceuticals, INC. | $105.74 | 2023-2025 | Jardiance |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $88.76 | 2023-2025 | Xifaxan, Trulance |
| Glaxosmithkline, LLC. | $81.52 | 2023-2025 | Arexvy, Shingrix |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $72.21 | 2023-2025 | Cologuard Collection Kit |
| Abbott Laboratories | $69.96 | 2024-2025 | Freestyle Libre 3 |
| Dexcom, INC. | $61.58 | 2025 | Dexcom G6 Transmitter |
| Viiv Healthcare Company | $61.38 | 2025 | Dovato |
| Indivior INC. | $52.76 | 2024 | Sublocade |
| Sanofi-Aventis U.S. LLC | $43.03 | 2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $41.60 | 2024 | Caplyta |
| Jazz Pharmaceuticals INC. | $35.82 | 2025 | |
| Boston Scientific Corporation | $28.61 | 2025 | Wavewriter Alpha Prime 16 |
| Gilead Sciences, INC. | $28.30 | 2024 | |
| Xeris Pharmaceuticals, INC. | $23.82 | 2023 | Gvoke Hypopen |
| Lundbeck LLC | $22.10 | 2024 | Rexulti |
| Phathom Pharmaceuticals, INC. | $20.95 | 2024 | Voquezna |
| Corcept Therapeutics | $20.17 | 2025 | Korlym |
| Sumitomo Pharma America, INC. | $14.91 | 2025 | Gemtesa |
| Janssen Pharmaceuticals, INC | $14.86 | 2025 | Spravato |
| Esperion Therapeutics, INC. | $14.82 | 2025 | Nexletol |
| Mannkind Corporation | $14.11 | 2023 | Afrezza |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ryan Shephard listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.